{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:26:00Z","timestamp":1772778360271,"version":"3.50.1"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,3,14]]},"DOI":"10.18632\/oncotarget.28563","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T13:33:20Z","timestamp":1710423200000},"page":"220-231","source":"Crossref","is-referenced-by-count":6,"title":["ABT199\/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells"],"prefix":"10.18632","volume":"15","author":[{"given":"Benigno C.","family":"Valdez","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy L.","family":"Ramdial","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"1","volume-title":"The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT","author":"Babic","year":"2018"},{"key":"2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"1","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Galinsky","year":"2014","journal-title":"Cancer Discov"},{"key":"4","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"10","author":"Stein","year":"2018","journal-title":"Haematologica"},{"key":"5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"13","author":"Chyla","year":"2019","journal-title":"Blood"},{"key":"6","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3109\/10428194.2014.889825","article-title":"Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma","volume":"5","author":"Bredeson","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clml.2013.08.006","article-title":"The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation","volume":"1","author":"Qazilbash","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12185-021-03263-y","article-title":"An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma","volume":"11","author":"Kondo","year":"2022","journal-title":"Int J Hematol"},{"key":"9","doi-asserted-by":"publisher","first-page":"e30322","DOI":"10.1002\/pbc.30322","article-title":"Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders","volume":"7","author":"Horn","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell transplantation","volume":"1","author":"Andersson","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bcp.2010.09.027","article-title":"The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling","volume":"8","author":"Andersson","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"1","author":"Shpall","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12185-018-2431-5","article-title":"Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML","volume":"10","author":"Naik","year":"2018","journal-title":"Int J Hematol"},{"key":"14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41409-022-01705-7","article-title":"A randomized phase III study of pretransplant conditioning for AML\/MDS with fludarabine and once daily IV busulfan \u00b1 clofarabine in allogeneic stem cell transplantation","volume":"5","author":"Kawedia","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1182\/bloodadvances.2021005224","article-title":"Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen","volume":"6","author":"Bierings","year":"2022","journal-title":"Blood Adv"},{"key":"16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.exphem.2015.02.001","article-title":"Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators","volume":"4","author":"Andersson","year":"2015","journal-title":"Exp Hematol"},{"key":"17","first-page":"211","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation","author":"Appelbaum","year":"2016","edition":"5th Ed"},{"key":"18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.18632\/oncotarget.28193","article-title":"ABT199\/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells","volume":"1","author":"Andersson","year":"2022","journal-title":"Oncotarget"},{"key":"19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00894-010-0658-z","article-title":"Some physicochemical properties of the antitumor drug thiotepa and its metabolite tepa as obtained by density functional theory (DFT) calculations","volume":"1","author":"Ouamerali","year":"2010","journal-title":"J Mol Model"},{"key":"20","doi-asserted-by":"publisher","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","article-title":"Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells","volume":"27","author":"Smulson","year":"1999","journal-title":"J Biol Chem"},{"key":"21","doi-asserted-by":"publisher","first-page":"75774","DOI":"10.18632\/oncotarget.12411","article-title":"TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death","volume":"7","author":"Sch\u00fctze","year":"2016","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12192-020-01161-6","article-title":"Cleavage of HSP90\u03b2 induced by histone deacetylase inhibitor and proteasome inhibitor modulates cell growth and apoptosis","volume":"2","author":"Lee","year":"2021","journal-title":"Cell Stress Chaperones"},{"key":"23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1667\/RR3308.2","article-title":"Histone modifications and DNA double-strand break repair after exposure to ionizing radiations","volume":"17","author":"Pandita","year":"2013","journal-title":"Radiat Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/978-1-61779-998-3_40","article-title":"Histone H2AX phosphorylation: a marker for DNA damage","volume":"92","author":"Almasan","year":"2012","journal-title":"Methods Mol Biol"},{"key":"25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","article-title":"Cellular functions of the protein kinase ATM and their relevance to human disease","volume":"2","author":"Paull","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"26","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1074\/jbc.M112355200","article-title":"Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes","volume":"27","author":"Izumo","year":"2002","journal-title":"J Biol Chem"},{"key":"27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3892\/ijo.2015.3052","article-title":"The phosphatidylinositol 3-kinase\/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review)","volume":"4","author":"Tony To","year":"2015","journal-title":"Int J Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.bbadis.2013.06.013","article-title":"Phosphorylation and degradation of S6K1 (p70S6K1) in response to persistent JNK1 Activation","volume":"183","author":"Ye","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.cr.7290049","article-title":"DNA fragmentation in apoptosis","volume":"1","author":"Xu","year":"2000","journal-title":"Cell Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"9","author":"Konopleva","year":"2012","journal-title":"Ann Hematol"},{"key":"31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"5","author":"Tibes","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"38","author":"Leber","year":"2020","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"publisher","first-page":"562558","DOI":"10.3389\/fonc.2020.562558","article-title":"Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions","volume":"1","author":"DiNardo","year":"2020","journal-title":"Front Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia","volume":"4","author":"Short","year":"2022","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/35043058","article-title":"The many substrates and functions of ATM","volume":"1","author":"Lim","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"36","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"29","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"37","doi-asserted-by":"publisher","first-page":"119187","DOI":"10.1016\/j.bbamcr.2021.119187","article-title":"Heat shock proteins in cell signaling and cancer","volume":"186","author":"Calderwood","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"38","first-page":"105","article-title":"Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma","volume":"3","author":"Tang","year":"2011","journal-title":"Int J Oncol"},{"key":"39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.exphem.2012.06.001","article-title":"Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines","volume":"4","author":"Andersson","year":"2012","journal-title":"Exp Hematol"},{"key":"40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Kadia","year":"2016","journal-title":"Cancer Discov"},{"key":"41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccell.2019.01.013","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"3","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"42","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: Rationale and progress","volume":"4","author":"Stein","year":"2020","journal-title":"Blood Rev"},{"key":"43","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: from cellular function and regulation to pharmacological inhibition","volume":"28","author":"Orz\u00e1ez","year":"2022","journal-title":"FEBS J"},{"key":"44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"3","author":"Sallman","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"10","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"46","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.leukres.2008.01.016","article-title":"Altered gene expression in busulfan-resistant human myeloid leukemia","volume":"3","author":"Andersson","year":"2008","journal-title":"Leuk Res"},{"key":"47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"6","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"48","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1084\/jem.182.5.1545","article-title":"Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl","volume":"18","author":"Green","year":"1995","journal-title":"J Exp Med"},{"key":"49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"2","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T13:33:31Z","timestamp":1710423211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3,14]]}},"alternative-id":["28563"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28563","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}